Edition:
United States

Jiangsu Sihuan Bioengineering Co Ltd (000518.SZ)

000518.SZ on Shenzhen Stock Exchange

7.02CNY
26 May 2017
Change (% chg)

¥0.04 (+0.57%)
Prev Close
¥6.98
Open
¥6.98
Day's High
¥7.10
Day's Low
¥6.98
Volume
2,151,371
Avg. Vol
5,930,368
52-wk High
¥9.77
52-wk Low
¥6.25

Latest Key Developments (Source: Significant Developments)

Jiangsu Sihuan Bioengineering says Xu Yin resigns from CFO
Thursday, 25 May 2017 02:53am EDT 

May 25(Reuters) - Jiangsu Sihuan Bioengineering Co Ltd <000518.SZ> ::* Says Xu Yin resigned from co's CFO, due to personal reason.  Full Article

Jiangsu Sihuan Bioengineering sees Q1 2017 net profit to be about 14 mln yuan
Sunday, 16 Apr 2017 11:41pm EDT 

April 17 (Reuters) - Jiangsu Sihuan Bioengineering Co Ltd <000518.SZ>: :* Sees net profit for Q1 2017 to be about 14 million yuan, compared to net loss of the same period in 2016 (955,200 million yuan).* Comments that increased sales in Beijing unit and investment income are the main reasons for the forecast.  Full Article

Jiangsu Sihuan Bioengineering completes stake exchange for investment firm
Wednesday, 25 Jan 2017 10:51pm EST 

Jiangsu Sihuan Bioengineering Co Ltd <000518.SZ> : Says co completes using 12 percent stake in co's wholly owned bio-pharma unit in exchange for 100 percent stake in a Guangxi-based investment firm .Says the equity delivery procedures has been completed.  Full Article

Jiangsu Sihuan Bioengineering sees FY 2016 net profit up 101.3 pct to 124.2 pct
Friday, 20 Jan 2017 03:32am EST 

Jiangsu Sihuan Bioengineering <000518.SZ>: Sees net profit for FY 2016 up 101.3 percent to 124.2 percent, or to be 1 million yuan to 18 million yuan . Says the net loss of FY 2015 was 74.4 million yuan .Comments gain on selling subsidiary is the main reason for the forecast.  Full Article

Jiangsu Sihuan Bioengineering to divest stake in Xinjiang-based new energy firm
Friday, 30 Sep 2016 11:12am EDT 

Jiangsu Sihuan Bioengineering Co Ltd <000518.SZ> : Says co and co's unit plans to sell 44.12 percent and 26.85 percent stake in a Xinjiang-based new energy technology firm to a Jiangsu-based investment, for totaling 11 million yuan .Says co and unit will hold no stake in the Xinjiang-based new energy firm after the transaction.  Full Article

Jiangsu Sihuan Bioengineering says lawsuit files by investment firm
Thursday, 4 Aug 2016 01:41am EDT 

Jiangsu Sihuan Bioengineering Co Ltd <000518.SZ>: Says a Guangzhou-based investment firm filed lawsuit to against the co regarding a change in an independent director position of the co .Says the investment firm demands the co to withdraw the decision that passed by shareholders' meeting.  Full Article

Jiangsu Sihuan Bioengineering expects to post 1-5 mln yuan net loss in 2016 H1
Friday, 15 Jul 2016 04:06am EDT 

Jiangsu Sihuan Bioengineering Co., Ltd. <000518.SZ>: Says it expects 2016 H1 net loss of 1-5 million yuan .Says 2015 H1 net income was 4.1 million yuan.  Full Article

Jiangsu Sihuan Bioengineering announces no dividend payment for 2015
Thursday, 28 Apr 2016 08:00pm EDT 

Jiangsu Sihuan Bioengineering Co Ltd:Says the company will pay no dividend to shareholders for 2015.  Full Article

Jiangsu Sihuan Bioengineering issues Q1 2016 net loss outlook
Thursday, 14 Apr 2016 08:00pm EDT 

Jiangsu Sihuan Bioengineering Co Ltd:Sees net loss outlook for Q1 of 2016 to be about 0.5 mln yuan ~ 3 mln yuan.Says the net profit of Q1 of 2015 was 10.098 mln yuan.Comments that decreased profit in subsidiaries is the main reason for the forecast.  Full Article

Jiangsu Sihuan Bioengineering subsidiary receives GMP certificate
Thursday, 3 Mar 2016 07:00pm EST 

Jiangsu Sihuan Bioengineering Co Ltd:Wholly owned Jiangsu-based biopharmaceutical subsidiary received goods manufacture practice (GMP) certificate from Jiangsu Food and Drug Administration Bureau.Certificate issued to bulk drug manufactured by the subsidiary and the valid period is until Feb. 2, 2021.  Full Article

More From Around the Web

BRIEF-Jiangsu Sihuan Bioengineering to use stake in unit in exchange for investment firm

* Says it plans to use 12 percent stake in its wholly owned bio-pharma unit in exchange for 100 percent stake in a Guangxi-based investment firm from Guangxi-based forestry development firm

No consensus analysis data available.